?
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓÚ²³½¡½ñÈÕÐû²¼£¬ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö(FDA)ÒѽÓÊÜÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾100mg /mL×¢ÉäÒºLEQEMBI?(lecanemab-irmb)Ôö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇë(sBLA)£¬ÓÃÓÚ¾²Âö×¢É䣬ÒÔÖ§³ÖLEQEMBI¼ÓËÙÉóÅúÏò´«Í³ÉóÅúµÄת±ä¡£LEQEMBI?ÉêÇëÒÑ»ñµÃÓÅÏÈÉóÆÀ×ʸñ£¬´¦·½Ò©Óû§ÊÕ·Ñ·¨°¸(PDUFA)µÄÉúЧÈÕÆÚΪ2023Äê7ÔÂ6ÈÕ¡£FDAÄ¿Ç°Õý¼Æ»®ÕÙ¿ª×ÉѯίԱ»áÌÖÂÛ¸ÃÉêÇ룬µ«ÉÐδ¹ûÈ»Ðû²¼»áÒéÈÕÆÚ¡£
LEQEMBI?ÊÇÒ»ÖÖÕë¶Ô¾Û¼¯¿ÉÈÜÐÔ(¡°ÔÏËά¡±)ºÍ²»ÈÜÐÔµí·ÛÑùÂѰצ£¨A¦Â£©ÐÎʽµÄÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ì壬ÓÚ2023Äê1ÔÂ6ÈÕFDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡(AD)¡£LEQEMBI?½öÊÊÓÃÓÚÖÎÁÆÇá¶ÈÈÏÖªÕÏ°»ò´¦ÓÚÇá¶È³Õ´ôÆÚ²¢Ö¤Êµ´æÔÚA¦Â²¡ÀíµÄ»¼Õß¡£ÔÚLEQEMBI?»ñµÃÅú×¼µ±Ì죬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«Ñ¸ËÙÏòFDAÌá½»Ôö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇ루sBLA£©£¬ÒÔ±ãÔÚ´«Í³Í¾¾¶Ï½øÐÐÉóÅú¡£sBLAÊÇ»ùÓÚÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾×î½ü·¢±íµÄ´óÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚÁÙ´²ÊÔÑéClarity ADµÄÑо¿½á¹ûÀ´Ìá½»µÄ¡£LEQEMBI?Âú×ãÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖյ㣬½á¹û¾ßÓÐÏÔÖøͳ¼ÆѧÒâÒå¡£2022Äê11Ô£¬Clarity ADÑо¿µÄ½á¹ûÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑé(CTAD)»áÒéÉÏ·¢±í£¬²¢Í¬Ê±·¢±íÔÚͬÐÐÆÀÉóµÄҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£
LEQEMBI?ÒÑÔÚÃÀ¹ú»ñµÃÅú×¼£¬²¢ÓÚ2023Äê1ÔÂ18ÈÕÔÚÃÀ¹úÍƳö¡£¸ÃÅú×¼ÊÇ»ùÓÚIIÆÚÊý¾Ý£¬ÕâЩÊý¾Ý±íÃ÷LEQEMBI¼õÉÙÁËA¦Â°ß¿éÔÚ´óÄÔÖеĻýÀÛ£¬ÕâÊÇADµÄÒ»¸ö¾ö¶¨ÐÔÌØÕ÷£¬Æä¼ÌÐøÅú×¼½«È¡¾öÓÚÔÚÑéÖ¤ÐÔÊÔÑéÖÐÑéÖ¤LEQEMBI?µÄÁÙ´²ÓÅÊÆ¡£FDAÒÑÈ·¶¨Clarity ADµÄ½á¹û¿É×÷ΪÑéÖ¤lecanemabÁÙ´²»ñÒæµÄÑéÖ¤ÐÔÑо¿¡£
LEQEMBI?µÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹ㡣ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£
MEDIA CONTACT:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com
Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net
INVESTOR CONTACT:
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Natacha Gassenbach
+ 1-857-777-6573
public.affairs@biogen.com
Mike Hencke
+ 1-781-464-2442
IR@biogen.com